학술논문
Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15387445